NY-SECURITYSCORECARD
12.9.2022 10:02:00 CEST | Business Wire | Press release
Leading IT services provider NTT DATA UK&I and SecurityScorecard, the global leader in cyber security ratings, today announced a new partnership to accelerate the transformation of continuous cyber risk monitoring across industries across the UK and Ireland (UK&I). As part of the partnership, NTT DATA will deliver an innovative posture evaluation report offering for clients, based on the SecurityScorecard platform. The report will combine NTT DATA’s consulting expertise with SecurityScorecard’s ratings and assessment capabilities to instantly rate, analyse and continuously monitor security risk for clients, as well as harden their security postures.
In today’s ever-evolving cyber security landscape, organisations must be proactive in addressing cyber breaches, and security ratings are integral to measuring and understanding resilience in real time. NTT DATA understands the importance of this and is doubling its efforts in the cyber security space as a result, ensuring its clients are best equipped to handle new threats on a regular basis. It is for this reason that SecurityScorecard has joined the likes of Adobe and Microsoft in becoming a Tier 1 strategic partner for NTT DATA UK&I.
From non-executive directors through to IT operations teams, businesses’ stakeholders call out three critical board-level risks – data loss, cyber breach, and third-party exposure. These risks are typically grounded in common challenges, such as enterprise visibility, poor information clarity or translation, and confused response prioritisation, but are stressed further by an industry-wide shortage of competent security knowledge and skills. The partnership between NTT DATA and SecurityScorecard will address these client challenges head-on, bringing together industry-leading core competencies, industry sector insights, deep client knowledge, and strategic client relationships.
Mike Jones, VP of Partners & Alliances at NTT DATA (UK&I), commented: “NTT DATA is proud of its global ecosystem of Partners & Alliances, which helps bring value to our clients through transformational change. We’re delighted to announce our latest partnership with SecurityScorecard, the global leader in cybersecurity ratings, to help NTT DATA identify security threats as well as keep clients safe and secure.”
SecurityScorecard provides comprehensive security ratings, automated assessments, and guidance from industry experts, providing easy-to-understand A-F graded scorecards for improved communication, effective compliance reporting and more informed decision making. The solution allows organisations to automate and accelerate questionnaire exchange with over 20 compliance survey templates and questionnaires at scale.
“Our partnership with NTT DATA immediately gives customers in EMEA more complete visibility into the risks that exist in their environment, and guidance in reducing that risk most effectively, all in a single platform,” said Jan Bau, VP EMEA and LATAM at SecurityScorecard. “This will enable organisations across NTT DATA’s portfolio to proactively ensure they have continuous and immediate insights on their security posture.”
Through the partnership, SecurityScorecard will embed a suite of cyber security monitoring solutions into NTT DATA’s managed service offering to create a monthly posture evaluation report. The report will allow businesses to understand their true cyber risk and will enable them to instantly improve their security postures through much-needed data, visibility, and insights. As well as insights from the platform, the monthly service will benefit from NTT DATA’s advisory and threat intelligence capabilities, providing not just an overview of a client’s industry sector, but an overview of their vendors and business partners as well, delivering additional value to clients in the areas they want to target the most.
Jones added, “NTT DATA places huge importance on cyber resilience and our new posture evaluation solution has been built to provide our clients with peace of mind when it comes to their cyber security. Not only will our reporting tool share a holistic overview of their security measures, but clients will be able to rest easy knowing they have identified all potential areas of vulnerability and implemented the right solutions to protect their critical infrastructure.”
For more information about SecurityScorecard and NTT DATA UK&I, visit the SecurityScorecard booth at the Gartner UK Security & Risk Summit, Stand 105 from September 12 through the 14.
About NTT DATA
NTT DATA is the world’s second largest managed security services provider, with over 5,500 information and cyber security professionals globally. Headquartered in Tokyo, and with business operations in over 50 countries, NTT DATA’s security practice provides Security Consulting, Engineering, Managed Services and accelerated partnered product solutions that align with its clients’ business goals, as well as meet speed, cost, quality, and regulatory needs. NTT DATA’s emphasis is on long-term commitment, combining Security Operations Centres (SOCs) and local delivery capabilities to provide premier professional services on a global scale. For more information, visit: uk.nttdata.com
About SecurityScorecard
Funded by world-class investors including Evolution Equity Partners, Silver Lake Waterman, Sequoia Capital, GV, Riverwood Capital, and others, SecurityScorecard is the global leader in cybersecurity ratings with more than 12 million companies continuously rated. Founded in 2013 by security and risk experts Dr. Aleksandr Yampolskiy and Sam Kassoumeh, SecurityScorecard's patented rating technology is used by over 30,000 organisations for enterprise risk management, third-party risk management, board reporting, due diligence, cyber insurance underwriting, and regulatory oversight. SecurityScorecard is the first cybersecurity ratings company to offer digital forensics and incident response services, providing a 360-degree approach to security prevention and response for its worldwide customer and partner base. SecurityScorecard continues to make the world a safer place by transforming the way companies understand, improve and communicate cybersecurity risk to their boards, employees and vendors. Every organisation has the universal right to their trusted and transparent Instant SecurityScorecard rating. For more information, visit securityscorecard.com or connect with us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005192/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
